At the 2018 high-level United Nations meeting on tuberculosis (TB), treatment targets were set for the 5-year period 2018–2022. These targets included the treatment of 3.5 million children. However, by 2020 only 41% of this target had been achieved with further stasis highly likely due to the havoc wreaked by the COVID-19 pandemic on access to healthcare. Tuberculous meningitis (TBM), is considered the most devastating manifestation of TB, with the peak incidence in the vulnerable early childhood age group, coinciding with critical brain development. Early diagnosis in childhood is difficult due to nonspecific clinical features and the paucibacillary nature of the disease complicating cerebrospinal fluid (CSF) mycobacterial confirmation, resulting in delayed diagnosis and treatment. Untreated, TBM is uniformly fatal, and even when treated, the neurological sequelae can be severe. Unfortunately, the evidence to guide treatment is limited. We present a summary of existing pediatric TBM treatment, recent updates, clinical trials which may potentially inform antituberculous dosing regimens, and practical clinical recommendations.
Description: This is an author accepted manuscript version of an article accepted for publication, and following peer review. Please be aware that minor differences may exist between this version and the final version if you wish to cite from it.
Licence: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0